Phreesia (NYSE:PHR) CFO Sells $19,788.60 in Stock

Key Points

• Phreesia CFO Balaji Gandhi sold 885 shares of Phreesia stock for approximately $19,788.60, reducing his ownership by 0.89% to 98,240 shares.
• The company's shares recently traded at $23.11, with a market capitalization of $1.38 billion and a price-to-earnings ratio of -55.02.
• Phreesia reported a 14.9% increase in quarterly revenue year-over-year, totaling $117.26 million, and reported earnings per share of $0.01, exceeding analysts' expectations.

Phreesia, Inc. (NYSE:PHR - Get Free Report) CFO Balaji Gandhi sold 885 shares of the business's stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $22.36, for a total transaction of $19,788.60. Following the completion of the sale, the chief financial officer owned 98,240 shares in the company, valued at $2,196,646.40. The trade was a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, September 16th, Balaji Gandhi sold 4,183 shares of Phreesia stock. The stock was sold at an average price of $23.28, for a total transaction of $97,380.24.

Phreesia Price Performance

Shares of NYSE PHR traded up $0.17 during midday trading on Tuesday, reaching $23.11. The company's stock had a trading volume of 370,773 shares, compared to its average volume of 611,887. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average price of $26.02 and a 200 day moving average price of $25.99. Phreesia, Inc. has a one year low of $17.07 and a one year high of $32.76. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -55.02 and a beta of 0.68.

Phreesia (NYSE:PHR - Get Free Report) last released its earnings results on Thursday, September 4th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.08. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The business had revenue of $117.26 million for the quarter, compared to the consensus estimate of $116.39 million. During the same period in the previous year, the firm earned ($0.03) EPS. The business's revenue for the quarter was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. On average, equities research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Mizuho assumed coverage on shares of Phreesia in a report on Wednesday, August 27th. They set an "outperform" rating and a $36.00 price target on the stock. Piper Sandler boosted their price target on shares of Phreesia from $33.00 to $34.00 and gave the company an "overweight" rating in a report on Friday, September 5th. DA Davidson upgraded shares of Phreesia to a "strong-buy" rating in a report on Monday, September 8th. JMP Securities boosted their price target on shares of Phreesia from $30.00 to $34.00 and gave the company a "market outperform" rating in a report on Monday, September 8th. Finally, Truist Financial boosted their price target on shares of Phreesia from $35.00 to $36.00 and gave the company a "buy" rating in a report on Friday, September 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $33.85.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Phreesia by 2.4% in the 1st quarter. Vanguard Group Inc. now owns 4,936,515 shares of the company's stock valued at $126,177,000 after buying an additional 113,405 shares during the period. Greenhouse Funds LLLP increased its stake in Phreesia by 12.5% in the 2nd quarter. Greenhouse Funds LLLP now owns 3,325,262 shares of the company's stock valued at $94,637,000 after buying an additional 368,352 shares during the period. Champlain Investment Partners LLC increased its stake in Phreesia by 20.0% in the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company's stock valued at $75,312,000 after buying an additional 490,340 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Phreesia by 108.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock valued at $67,606,000 after buying an additional 1,377,904 shares during the period. Finally, Franklin Resources Inc. increased its stake in Phreesia by 0.6% in the 2nd quarter. Franklin Resources Inc. now owns 1,524,251 shares of the company's stock valued at $43,380,000 after buying an additional 9,057 shares during the period. Institutional investors and hedge funds own 92.10% of the company's stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.